MedTrace Logo

Effects of Creatine Supplementation on Cognitive Measures and Markers of Acute Kidney Injury After Exercise in the Heat

NCT07472426 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2026-03-16

No results posted yet for this study

Summary

The goal of this clinical trial is to learn if one week of creatine monohydrate supplementation alters inflammation, markers of acute kidney injury (AKI) risk, and cognitive performance in active, young, healthy volunteers. The main questions it aims to answer are:

1. Does one-week of creatine supplementation alter urinary markers of inflammation (cytokines) during exercise in the heat when compared to placebo?
2. Does one-week of creatine supplementation alter markers of AKI during exercise in the heat when compared to placebo?
3. Does one-week of creatine supplementation attenuate reductions in cognitive measures as a response of fatigue from exertional heat stress.

Researchers will compare creatine monohydrate to a placebo (maltodextrin) to see if it alters inflammation, risk of acute kidney injury, and cognition after exercise in the heat.

Participants will :

* Complete a baseline aerobic exercise test to measure VO2max
* Ingest 20 grams per day of creatine monohydrate or placebo (maltodextrin) for seven consecutive days
* Cycle for 90 minutes in a heated chamber (38 C, \~40% relative humidity), alternating low- and high-intensity exercise
* Self-collect urine before, after, and one-hour after exercise
* Self-insert a rectal thermistor to measure core temperature
* Complete cognitive tasks using the NIH toolbox before and after exercise to assess cognition
* Complete the other condition (placebo or creatine) at least 21 days later

Conditions

Interventions

DIETARY_SUPPLEMENT

Creatine Monohydrate

20 grams per day of creatine monohydrate for 7 days, followed by 1 day of 5 grams of supplementation.

DIETARY_SUPPLEMENT

Maltodextrin (Placebo)

Participants will ingest 20 grams per day for 7 days, followed by 1 day of 5 grams.

Sponsors & Collaborators

  • University of Northern Iowa

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2026-03-12
Primary Completion
2027-03-31
Completion
2027-05-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07472426 on ClinicalTrials.gov